Company Overview of Osaka University
Osaka University is an educational institution.
Founded in 2004
Key Executives for Osaka University
Osaka University does not have any Key Executives recorded.
Osaka University Key Developments
Eli Lilly and Osaka University Enter into Research Collaboration on Obesity
Sep 5 16
Eli Lilly (US) and Osaka University (Japan) have agreed to set up a research collaboration focusing on the prevention of obesity prevention. Under the agreement, Eli Lilly's China-based research and development (R&D) centre will collaborate with researchers at Osaka University on obesity prevention measures, focusing in particular on the process of obesity progression in relation to diabetes pathophysiology. The collaboration is expected to focus on potential modes of treatment for the prevention of obesity, based on Osaka University's initial research on progression of the disease. In addition, Eli Lilly's China-based R&D centre is expected to potentially have access to data based on local Asian patient populations, which would give the company an advantage in applying for marketing approval in China for any treatment candidates that may result from the collaboration.
Rohto Pharmaceutical and Osaka University Enter into Stem-Cell Research Partnership
Aug 9 16
Rohto Pharmaceutical and Osaka University's Graduate School of Medicine have entered into a research partnership focusing on accelerating the commercialisation of mesenchymal stem-cell-based regenerative treatments. Under the agreement, the two parties will use Rohto's stem cells to carry out research into serious heart failure, as well as evaluate pharmacological study models and conduct preclinical research. Depending on the outcome of the research, the partnership aims to conduct an investigator-initiated clinical trial, with the aim of receiving conditional approval for a regenerative treatment. Rohto also plans to consider future partnerships with Osaka University to explore other clinical applications of its mesenchymal stem cells.
Osaka University and Chugai Announce Comprehensive Collaboration Agreement
May 19 16
Osaka University and Chugai Pharmaceutical Co. Ltd. announced the conclusion of a comprehensive collaboration agreement for advanced research in immunology between the Osaka University Immunology Frontier Research Center (IFReC) and Chugai. This comprehensive collaboration will maintain an academic environment that allows researchers at IFReC to focus on basic research originating from their own ideas, with the aim of contributing back to society the results of the advanced immunology research. In addition, through the combination of the global top-class research in immunology at IFReC and the knowledge of innovative drug research accumulated by Chugai through its proprietary technologies, the obstacles between basic research and clinical application research will be eliminated.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries